The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
12-Mar-09
$46.9 billion
Target:
Genentech, Inc.
Acquiror:
Roche Holding Ltd.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of the outstanding publicly held interest in Genentech, Inc., a leading biotechnology company
27-Jul-15
$40.5 billion
Target:
Allergan Generics
Acquiror:
Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
18-Feb-14
$25.1 billion
Target:
Forest Laboratories Inc.
Acquiror:
Actavis plc
Advised Actavis plc, a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products on its acquisition of Forest Laboratories Inc.
09-Mar-09
$18.6 billion
Target:
Rohm & Haas Company
Acquiror:
The Dow Chemical Company
Advised The Dow Chemical Company during its negotiations pertaining to the Rohm & Haas settlement resolution
14-Apr-08
$17.7 billion+
Target:
Northwest Airlines
Acquiror:
Delta Air Lines
Advised Delta Air Lines in connection with its merger with Northwest Airlines (+Transaction value represents enterprise value of combined entity)
26-Jan-15
$16.0 billion
Target:
MeadWestvaco Corporation
Acquiror:
Rock-Tenn Company
Provided fairness opinion to the Board of Directors of MeadWestvaco on the merger with RockTenn to create a powerful global provider of consumer and corrugated packaging solutions
26-Nov-12
$16 billion
Target:
Archstone Enterprise LP
Acquiror:
AvalonBay Communities & Equity Residential
Advised AvalonBay on its joint acquisition with Equity Residential of the assets and liabilities of Archstone Enterprise LP, an owner of high-quality apartment communities in major markets in the United States, from Lehman Brothers Holdings
15-Dec-10
$12.9 billion
Target:
Alcon, Inc.
Acquiror:
Novartis AG
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company
28-Mar-12
$10.4 billion+
Target:
Flow Control Business of Tyco International Ltd.
Acquiror:
Pentair, Inc.
Provided fairness opinion to the Board of Directors of Pentair, Inc. in connection with its all-stock merger with Tyco Flow Control, a division of Tyco International Ltd. (+Transaction value represents enterprise value of combined entity)
20-May-13
$8.5 billion
Target:
Warner Chilcott, plc
Acquiror:
Actavis, Inc.
Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc
19-Feb-15
$8.4 billion
Target:
Rexam plc
Acquiror:
Ball Corporation
Advised Ball Corporation, a leading manufacturer of metal packaging products for the global beverage, food, personal care and household products industries as well as a provider of systems and technologies for the aerospace industry, on the acquisition of Rexam plc, a leading beverage can manufacturer
11-Oct-22
Pending
$7.9 billion
Target:
Westinghouse Electric Company
Acquiror:
Brookfield Renewable Partners and Cameco
Advising the Independent Committee of Brookfield Renewable Partners, the flagship listed renewable power company of Brookfield Asset Management, in consortium with Cameco and other institutional partners, on the acquisition of Westinghouse Electric Company, one of the world’s largest nuclear services businesses, from Brookfield Business Partners
20-Aug-12
$7.3 billion
Target:
Coventry Health Care Inc.
Acquiror:
Aetna
Advised Coventry Health Care Inc., a diversified managed health care company that offers a full portfolio of managed care products serving the commercial group and individual, Medicare Advantage, Medicare Part D and Medicaid markets, on its acquisition by Aetna
19-May-05
$7.2 billion+
Target:
US Airways Group
Acquiror:
America West Holdings
Advised America West Holdings in connection with its merger with US Airways Group. (+Transaction value represents enterprise value of combined entity, including capitalized operating leases of $4.8 billion)
12-Jun-08
$6.7 billion
Target:
Applied Biosystems Group
Acquiror:
Invitrogen Corporation
Provided fairness opinion to the Board of Directors of the Applera Corporation on the merger of its Applied Biosystems business, which serves the life science industry, with the Invitrogen Corporation, creating a global leader in biotechnology reagents and systems
22-May-07
$6.5 billion
Target:
Crescent Real Estate Equities Company
Acquiror:
Morgan Stanley Real Estate
Advised Crescent Real Estate Equities Company, a REIT holding a diversified portfolio of office properties, hotels and resorts and luxury residential developments on its sale to Morgan Stanley Real Estate
18-Dec-17
$6.0 billion
Target:
CB&I
Acquiror:
McDermott International, Inc.
Advised McDermott International, Inc., a leading provider of integrated engineering, procurement, construction, installation and module fabrication services for upstream field developments worldwide, on its combination with CB&I, a leading provider of technology and infrastructure for the energy industry
03-Aug-06
$6.0 billion
Target:
Reckson Associates Realty Corporation
Acquiror:
SL Green Realty Corporation
Advised the independent directors of Reckson, a real estate investment trust specializing in properties located in New York City and the surrounding Tri-State area, on the sale of Reckson to SL Green
19-Mar-07
$5.5 billion
Target:
The ServiceMaster Company
Acquiror:
Clayton, Dubilier & Rice
Provided fairness opinion to the Board of Directors of The ServiceMaster Company, a diversified consumer services business whose brands include Terminix, TruGreen and American Home Shield, in connection with its sale to private equity firm Clayton, Dubilier & Rice
30-Aug-12
$4.9 billion
Target:
Performance Coatings division of E. I. DuPont de Nemours and Company
Acquiror:
The Carlyle Group
Advised E. I. Du Pont de Nemours and Company, a global diversified chemicals company, on the sale of its Performance Coatings division to an affiliate of The Carlyle Group, a leading private equity firm
20-Apr-17
$4.3 billion
Target:
Brookfield Canada Office Properties
Acquiror:
Brookfield Property Partners L.P.
Advised the Special Committee of Brookfield Canada Office Properties, Canada’s pre-eminent office real estate investment trust, on its go private transaction with Brookfield Property Partners L.P.
06-Nov-06
$4.2 billion
Target:
Kos Pharmaceuticals, Inc.
Acquiror:
Abbott Laboratories
Advised Kos Pharmaceuticals, Inc., a specialty pharmaceutical provider of cardiovascular and respiratory drugs, on its sale to Abbott Laboratories
29-May-15
$4.1 billion
Target:
Telecity Group plc
Acquiror:
Equinix, Inc.
Advised Telecity Group plc, Europe’s leading provider of premium carrier-neutral data centres, on a recommended cash and share offer from Equinix, Inc. a leading US provider of colocation data centre services globally
15-Aug-18
$3.9 billion
Target:
Common shares and common share purchase warrants in Canopy Growth
Acquiror:
Constellation Brands
Advised Canopy Growth on a C$5bn investment by Constellation Brands. As consideration for the investment, Constellation received newly issued Canopy common shares and common share purchase warrants
10-Jun-20
$3.9 billion
Target:
Global collaboration agreement with Genmab A/S
Acquiror:
AbbVie, Inc
Advised AbbVie, Inc, an NYSE-listed global biopharmaceutical company, on a broad collaboration with Genmab A/S, a leading Danish-listed biotechnology company, to jointly develop and commercialise three next-generation bispecific antibody programs